Prolia (Denosumab) and Sildenafil Interaction: Safety, Risks, and Clinical Guidance

Why This Question Comes Up

Patients prescribed denosumab for osteoporosis often take multiple other medications. Sildenafil, prescribed for erectile dysfunction or pulmonary arterial hypertension, is one of the most commonly used PDE5 inhibitors worldwide. Because both drugs are frequently used in older adults (denosumab peaks in women over 60, sildenafil use is highest in men aged 50 to 70), clinicians and patients regularly ask whether the two can be combined safely.

The Short Answer

No direct pharmacokinetic or pharmacodynamic interaction between denosumab and sildenafil has been reported in peer-reviewed literature, FDA adverse-event databases, or major drug-interaction compendia such as Lexicomp or Micromedex. The drugs operate through entirely separate biological mechanisms and metabolic pathways [1][2].

Why Clinicians Still Screen for It

Standard practice is to screen every new prescription against a patient's full medication list. Denosumab's FDA label does note that hypocalcemia must be corrected before administration [1], and sildenafil's label warns about blood pressure reductions [2]. While these warnings do not implicate each other, a patient who is volume-depleted or hypocalcemic could theoretically experience compounded hemodynamic effects. That scenario is rare but worth understanding.

Pharmacokinetic Profile: No Metabolic Overlap

The interaction risk between two drugs often hinges on shared metabolic enzymes, transporter competition, or protein-binding displacement. Denosumab and sildenafil share none of these.

Denosumab Is a Monoclonal Antibody

Denosumab is a fully human IgG2 monoclonal antibody that binds RANK ligand (RANKL). It is not metabolized by cytochrome P450 enzymes, not a substrate or inhibitor of P-glycoprotein (P-gp), and not cleared renally or hepatically in the traditional sense [1]. Instead, it is catabolized through the reticuloendothelial system via nonspecific proteolysis, the same pathway that clears endogenous immunoglobulins. This means denosumab cannot inhibit, induce, or compete with the enzymes that metabolize small-molecule drugs.

Sildenafil Relies on CYP3A4 and CYP2C9

Sildenafil is a small-molecule PDE5 inhibitor metabolized primarily by CYP3A4 and to a lesser extent CYP2C9 [2]. Drugs that inhibit CYP3A4 (ketoconazole, ritonavir, erythromycin) raise sildenafil plasma levels, sometimes requiring dose reduction to 25 mg. Drugs that induce CYP3A4 (rifampin, phenytoin) lower sildenafil exposure. Denosumab does neither. A 2019 review of monoclonal antibody interactions in the Journal of Clinical Pharmacology confirmed that therapeutic antibodies do not modulate CYP activity at clinically relevant concentrations [3].

No P-gp or Transporter Concerns

Sildenafil is a substrate of P-gp and breast cancer resistance protein (BCRP), but denosumab, as a large-molecule biologic (~147 kDa), does not interact with these membrane transporters [1][3]. There is no plausible mechanism by which denosumab could alter sildenafil absorption, distribution, or elimination.

Pharmacodynamic Considerations

Even when two drugs lack metabolic overlap, pharmacodynamic interactions (where both drugs affect the same physiological system in ways that amplify or cancel effects) can be clinically meaningful. Denosumab and sildenafil act on entirely different systems, but two indirect concerns merit discussion.

Blood Pressure Effects

Sildenafil produces a mean systolic blood pressure reduction of 8.4 mmHg and diastolic reduction of 5.5 mmHg, as documented in the REVATIO and VIAGRA clinical programs [2]. Denosumab does not have any direct cardiovascular mechanism. It does not affect vascular tone, cardiac output, or autonomic reflexes.

The practical concern arises not from the denosumab-sildenafil pair itself but from the broader medication profile of the patient taking both. A 68-year-old man on amlodipine, lisinopril, denosumab, and sildenafil is not at risk because of a denosumab-sildenafil interaction. He is at risk because sildenafil plus two antihypertensives can produce symptomatic orthostatic hypotension. Denosumab is a bystander in that scenario.

Calcium and QT Interval

Denosumab can cause hypocalcemia, particularly in patients with chronic kidney disease (CKD stage 4-5), vitamin D deficiency, or malabsorption syndromes [1]. The FREEDOM trial (N=7,868) reported hypocalcemia in approximately 2% of denosumab-treated patients, though severe cases (grade 3-4) occurred in <0.1% [4]. Hypocalcemia can prolong the QT interval.

Sildenafil has not been associated with QT prolongation in standard pharmacology studies [2]. A 2014 analysis in Circulation actually suggested PDE5 inhibitors may have cardioprotective effects in certain heart-failure populations [5]. The risk of additive QT prolongation from combining these two drugs is therefore negligible, provided calcium levels are maintained within normal range.

Clinical Decision Framework: Should You Combine Them?

For most patients, the answer is yes, without dose adjustment to either drug. The following framework can guide the prescribing decision.

Step 1: Confirm No Nitrate Use

The single most dangerous interaction with sildenafil is concomitant nitrate therapy (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate). This combination is absolutely contraindicated due to severe, potentially fatal hypotension [2]. This has nothing to do with denosumab, but it must be verified in any patient starting or continuing sildenafil.

Step 2: Check Baseline Calcium and Vitamin D

Before each denosumab injection (administered every 6 months), serum calcium and 25-hydroxyvitamin D should be checked. The Endocrine Society recommends maintaining 25(OH)D above 20 ng/mL (50 nmol/L) before denosumab administration [6]. If calcium is low, correct it before the injection. This step applies regardless of sildenafil use.

Step 3: Review the Full Antihypertensive Regimen

If the patient takes alpha-blockers (tamsulosin, doxazosin), sildenafil dose should start at 25 mg due to additive hypotension risk [2]. This adjustment is independent of denosumab but relevant to the clinical picture.

Step 4: Assess Renal Function

In patients with eGFR <30 mL/min/1.73m², sildenafil clearance is reduced by approximately 50%, and starting doses of 25 mg are recommended [2]. These same patients are at higher risk for denosumab-induced hypocalcemia [1]. The two risks do not interact pharmacologically, but the patient population overlaps. Closer monitoring of calcium (every 2 weeks for the first month after injection in CKD 4-5) and conservative sildenafil dosing are both warranted.

What the Major Databases Say

Lexicomp and Micromedex

Neither Lexicomp nor Micromedex lists a denosumab-sildenafil interaction. These databases index interactions based on published case reports, pharmacokinetic studies, and mechanistic plausibility. The absence of a listing reflects the lack of any signal in published literature or post-marketing surveillance.

FDA Adverse Event Reporting System (FAERS)

A search of the FDA's FAERS database does not reveal a disproportionate signal for adverse events in patients co-prescribed denosumab and sildenafil. This does not prove safety with certainty (FAERS is a passive surveillance system with known reporting biases), but it adds to the evidence that this combination does not produce unexpected harm [7].

Drug Interaction Probability Scale

Using the Drug Interaction Probability Scale (DIPS) developed by Horn and Hansten, the denosumab-sildenafil pair scores 0 (highly improbable interaction) based on the absence of temporal association, mechanistic plausibility, rechallenge data, or supporting literature [8].

Special Populations

Postmenopausal Women Using Sildenafil for PAH

Sildenafil is FDA-approved for pulmonary arterial hypertension (PAH) under the brand name Revatio at 20 mg three times daily [2]. In women receiving denosumab for postmenopausal osteoporosis who also have PAH, the same principles apply. No dose adjustment is needed for either drug based on the combination. PAH patients should be monitored for systemic hypotension, but this reflects the sildenafil-PAH dynamic, not a denosumab effect.

Older Men on Testosterone Replacement Therapy

Men receiving testosterone replacement therapy (TRT) who also take sildenafil represent a common clinical scenario in hormone-therapy practice. If these men require denosumab for osteoporosis (testosterone deficiency is a known cause of male osteoporosis), all three medications can be used concurrently. Testosterone is metabolized by CYP3A4 and could theoretically compete with sildenafil for enzyme capacity, but denosumab remains uninvolved in that interaction [9].

Patients with Hepatic Impairment

Sildenafil exposure increases in patients with Child-Pugh A or B cirrhosis, and a starting dose of 25 mg is recommended [2]. Denosumab pharmacokinetics are not altered by hepatic impairment because it bypasses hepatic metabolism entirely [1]. No combined dose adjustment is required.

Patient Counseling Points

Timing of Administration

Denosumab is given as a 60 mg subcutaneous injection every 6 months in a clinical setting. Sildenafil is taken as needed (for ED) or three times daily (for PAH). There is no need to time sildenafil doses around denosumab injections.

Symptoms to Report

Patients should report dizziness, lightheadedness, or near-syncope, which would suggest excessive blood pressure lowering. They should also report muscle cramps, tingling in fingers or toes, or perioral numbness, which could indicate hypocalcemia following a denosumab injection. These symptom categories are unrelated to each other but may co-occur in the same time window by coincidence.

Calcium and Vitamin D Supplementation

The Prolia label recommends that all patients take calcium 1,000 mg/day and vitamin D 400 IU/day minimum [1]. This supplementation does not affect sildenafil pharmacokinetics or efficacy.

Drugs That Actually Interact with Denosumab

While sildenafil does not interact with denosumab, several drug classes do warrant caution.

Immunosuppressants

Corticosteroids and other immunosuppressive agents can compound the immunologic effects of denosumab, particularly regarding infection risk. The FREEDOM trial extension showed a slight numerical increase in serious infections with long-term denosumab use, and immunosuppressed patients may face higher risk [4].

Other Antiresorptive Agents

Concurrent use of denosumab with bisphosphonates (alendronate, zoledronic acid) is generally not recommended because both suppress osteoclast activity, and the combined effect on bone turnover markers has not been well studied in terms of long-term safety [6].

Drugs That Lower Calcium

Loop diuretics (furosemide), certain chemotherapy agents, and chelating agents can lower serum calcium. Combined with denosumab, these increase hypocalcemia risk. Monitoring should be intensified [1].

Drugs That Actually Interact with Sildenafil

Nitrates

Absolute contraindication. Combined nitrate-PDE5 inhibitor use can produce profound, treatment-resistant hypotension [2].

Strong CYP3A4 Inhibitors

Ritonavir increases sildenafil AUC by 1,100%. Ketoconazole increases it by 300%. Dose ceilings of 25 mg per 48 hours apply with strong CYP3A4 inhibitors [2].

Alpha-Blockers

Doxazosin 4 mg plus sildenafil 25 mg produced a mean additional standing systolic BP decrease of 7 mmHg in healthy volunteers, with symptomatic postural hypotension in some subjects [2]. A minimum 4-hour separation and 25 mg starting dose are standard recommendations.

The Bottom Line

Denosumab and sildenafil can be prescribed together without dose modification. The two drugs have zero metabolic overlap: denosumab is a monoclonal antibody cleared by immunoglobulin catabolism, while sildenafil is a small molecule metabolized by CYP3A4 and CYP2C9. No pharmacodynamic antagonism or synergistic toxicity has been identified. Verify calcium status before each denosumab injection, confirm that no nitrates are co-prescribed with sildenafil, and adjust sildenafil to 25 mg if the patient takes alpha-blockers or has eGFR <30 mL/min/1.73m².